e-learning
resources
Munich 2006
Sunday 03.09.2006
Lung cancer, haemoptoe, smoking and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The evaluation of dehydroepiandrosterone sulfate non-small cell lung cancer patients
D. Dworakowska, M. Lapinski, D. Tomaszewski, J. Skokowski, W. Rzyman, E. Czestochowska, K. Sworczak (Poland)
Source:
Annual Congress 2006 - Lung cancer, haemoptoe, smoking and COPD
Session:
Lung cancer, haemoptoe, smoking and COPD
Session type:
E-Posters in free access
Number:
348
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Dworakowska, M. Lapinski, D. Tomaszewski, J. Skokowski, W. Rzyman, E. Czestochowska, K. Sworczak (Poland). The evaluation of dehydroepiandrosterone sulfate non-small cell lung cancer patients. Eur Respir J 2006; 28: Suppl. 50, 348
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
Changes of lung function in patients with non-small cell lung cancer tretaed by chemotherapy
Source: Eur Respir J 2006; 28: Suppl. 50, 771s
Year: 2006
Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
Source: Eur Respir Rev 2015; 25: 65-70
Year: 2016
Advanced non-small cell lung cancer in elderly patients
Source: Breathe 2012; 9: 26-34
Year: 2012
Soluble non-invasive markers in non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 459s
Year: 2005
Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy
Source: Eur Respir J 2004; 24: Suppl. 48, 82s
Year: 2004
Expression of sex hormone receptors in non-small cell lung cancer patients
Source: Eur Respir J 2004; 24: Suppl. 48, 79s
Year: 2004
Radiotherapy in the treatment of nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 207–243
Year: 2009
Combined radiotherapy for nonsmall cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 31s
Year: 2003
Management of brain metastases in patients with non-small cell lung cancer
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
Effect of comorbidity on the prognosis of non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 385s
Year: 2006
New treatment options for nonsmall cell lung cancer and small cell lung cancer
Source: Annual Congress 2006 - PG12 - Small cell lung cancer management
Year: 2006
Update on nonsmall cell lung cancer
Source: Eur Respir Rev 2010 19: 173-185
Year: 2010
Anticancer treatment for advanced non-small cell lung cancer
Source: Breathe 2011; 8: 124-133
Year: 2011
Targeted therapy in non-small cell lung cancer
Source: Breathe 2012; 8: 206-215
Year: 2012
Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis
Source: Eur Respir J 2001; 18: Suppl. 33, 65s
Year: 2001
Second line therapy for advanced non-small cell lung cancer
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002
Comparison of clinic and pathological staging in non-small cell lung cancer
Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept